Dr. Miller conducts developmentally informed behavioral research to examine the impact of parent-youth communication and decision making on health-related behaviors and outcomes. She aims to conduct research that facilitates youth involvement and empowerment in health-related decision making and enhances parent-youth-provider relationships.
Dr. Zackular's research is focused on understanding how interactions between the host, gut microbiota, and pathogenic microbes impact human health and disease. His recent efforts center on understanding how the important nosocomial pathogen, Clostridium difficile, interacts with resident gut microbiota during infection and how interspecies cross-talk impacts growth, behavior, and virulence of this pathogen.
Dr. Hill seeks to understand how the immune system contributes to the two most common chronic diseases of childhood: allergy and obesity. He uses clinical and epidemiological information to guide basic and translational research on the genetic, epigenetic, and immunologic basis of these important conditions.
Dr. Katz’s investigates the sequelae of obesity and type 2 diabetes mellitus in youth. Her research involves the intersection of sleep, obesity, and glucose intolerance and prevention of cardiovascular risk. Her studies have led to the evaluation of quantitative tools important for assessment of metabolic risk in youth.
Dr. O'Connor investigates the immunological aspects of heart transplantation in children, specifically the impact of anti-HLA antibodies. The presence of these antibodies can complicate or even prevent a transplant from happening; therefore, reducing or eliminating them before transplant is important for a patient to receive a heart that is compatible with his or her immune system.
Dr. Yudkoff's research is focused on the use of stable isotopes to measure the rate of production of urea in humans who have a urea cycle defect, or a congenital inability to detoxify ammonia into urea.
Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.
Dr. Dowshen focuses on improving the health outcomes for adolescent and young adults (AYA) living with or at high risk for contracting HIV/AIDS and improving access and quality of care for gender expansive and transgender children and adolescents. She is particularly interested in developing and testing digital health interventions to reach, engage, and retain AYA in care.
Dr. Lin studies RNA modifications (a.k.a "epitranscriptomics") in human diseases, including cancer. She develops and applies high-throughput sequencing strategies and transcriptome engineering technologies to study the regulation and function of RNA modifications, including A-to-I RNA editing and m6A RNA methylation.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.